Drug Industry Patents Go Under Senate Judiciary Committee鈥檚 Microscope
During a hearing Tuesday, panel members focused on how drug companies have used patents to allegedly protect their competitive edge and profits.
Drug Costs
381 - 400 of 703 Results
-
-
Is Insulin’s High Cost Keeping Diabetes Patients From Taking Their Medicine?
An estimated 1.25 million Americans have Type 1 diabetes and cannot live without insulin. Sen. Kamala Harris鈥 claim that 1 in 4 diabetes patients cannot afford their insulin is a shockingly high number, so we decided to dig into the sparse data.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
Newsom: California Leads On Prescription Drugs
California Gov. Gavin Newsom claims that his state is 鈥渓eading the nation in holding drug companies accountable and fighting prescription drug prices.鈥 Is that really the case?
-
Klobuchar Wants To Stop 鈥楶ay-For-Delay鈥 Deals That Keep Drug Prices High
It鈥檚 as shady as it sounds.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Mulvaney: Trump Brought Down Drug Prices For The First Time In 50 Years
It鈥檚 "within spitting distance of something that鈥檚 true," said one health economist. But our fact check found it wasn't quite there.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Still More 鈥楳edicare-For-All鈥
Sarah Kliff of Vox.com, Margot Sanger-Katz of The New York Times and Paige Winfield Cunningham of The Washington Post join KHN鈥檚 Julie Rovner to discuss the latest version of a 鈥淢edicare-for-all鈥 bill by Sen. Bernie Sanders (I-Vt.), a presidential hopeful, and Democratic and Republican reactions to it. They also discuss the latest on congressional efforts to rein in drug prices and another state effort to expand Medicaid 鈥 but not exactly in the way voters wanted. Also, Rovner interviews Ceci Connolly of the Alliance of Community Health Plans.
-
The Blame Game: Everyone And No One Is Raising Insulin Prices
During Wednesday鈥檚 House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade鈥檚 300% price increase, frustrating congressional representatives.
By Rachel Bluth -
Can Someone Tell Me What A PBM Does?
The Senate Finance Committee鈥檚 third drug-pricing hearing focused on pharmacy benefit managers, and was more of a fact-finding mission on how these companies operate than a debate about policy proposals.
By Rachel Bluth -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Analysis: Why Americans Shouldn鈥檛 Feel Grateful For $137 Insulin
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.
-
Must-Reads Of The Week (Some Flying Below The Radar)
Executive editor Damon Darlin takes a spin as host of 鈥淭he Friday Breeze,鈥 whirling through a week of health care news so you don鈥檛 have to.
By Damon Darlin -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 The Karma Of Cutting Medicare
Stephanie Armour of The Wall Street Journal, Alice Ollstein of Politico and Rebecca Adams of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss the suggested cuts to health programs in President Donald Trump鈥檚 budget proposal, the latest on lawsuits challenging work requirements for Medicaid enrollees and the FDA鈥檚 crackdown on e-cigarettes. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week.
-
How Much Difference Will Eli Lilly’s Half-Price Insulin Make?
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Lawmakers United Against High Drug Prices Bare Partisan Teeth
Clear differences of opinion emerged between Democrats and Republicans during a House Ways and Means subcommittee hearing about how to make prescription drugs more affordable in the Medicare program.
By Rachel Bluth -
Cities And Counties Unlikely To Heed FDA Warning On Importing Foreign Drugs
The Food and Drug Administration claims CanaRX, a company used by more than 500 cities, counties and school districts to help their employees get cheaper drugs from overseas, has sent 鈥渦napproved鈥 and 鈥渕isbranded鈥 drugs to U.S. consumers, jeopardizing their safety.